Related Experiment Videos
[Metformin efficacious in poorly controlled diabetes mellitus type 2]
A M Stades1, F Holleman, J B Hoekstra
1Afd. Interne Geneeskunde, Diakonessenhuis Utrecht.
Nederlands Tijdschrift Voor Geneeskunde
|October 25, 2000
Summary
Metformin therapy improved glucose control in three patients, reducing HbA1c levels by 0.8-1.8%. While generally effective for diabetes management, gastrointestinal side effects like diarrhea occurred, necessitating dosage adjustments or discontinuation in some cases.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes management often requires optimizing glucose-lowering medications.
- Insulin and sulfonylurea derivatives are common therapies, but some patients exhibit insufficient glycemic control.
- Metformin is a widely used first-line agent for type 2 diabetes.
Observation:
- Three patients (60, 55, and 72 years old) with inadequate glucose regulation despite insulin or sulfonylurea therapy were initiated on metformin.
- Following metformin initiation, hemoglobin A1c (HbA1c) levels decreased by 0.8% to 1.8% across the patients.
- One patient experienced significant diarrhea, leading to metformin discontinuation.
Findings:
- Metformin therapy demonstrated a clinically significant improvement in glycemic control, evidenced by HbA1c reduction.
- Gastrointestinal side effects, particularly diarrhea, are common with metformin and can impact patient adherence and treatment continuation.
- While rare, serious adverse effects like lactic acidosis necessitate careful patient selection and monitoring for contraindications.
Implications:
- Metformin is an effective option for improving glycemic control in patients with suboptimal response to other diabetes medications.
- Managing metformin-associated side effects, especially gastrointestinal distress, is crucial for successful long-term treatment.
- Adherence to contraindications and vigilant monitoring are essential to mitigate the risks of serious metformin adverse events.